---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-030342"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2026-06-26T21:15:40+00:00"
generated_at: "2026-06-26T21:18:35.077907+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma receives NYSE American non-compliance notice; granted plan period through Oct 2027

## Summary
- Stockholders' equity of $3.02M as of March 31, 2026 fails the $4M minimum under Section 1003(a)(ii) of NYSE American Guide.
- Company also continues to be non-compliant with the $6M equity standard under Section 1003(a)(iii) as previously disclosed.
- NYSE American accepted the Company's plan to regain compliance, granting a plan period through October 2, 2027.
- Common stock will continue trading on NYSE American under symbol MTNB during the plan period; delisting proceedings possible if not compliant by deadline.

## SEC filing metadata
- accession: 0001493152-26-030342
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2026-06-26T21:15:40+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315226030342/0001493152-26-030342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315226030342/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-030342
- JSON: https://secwatch.observer/filing/0001493152-26-030342.json
- Plain text: https://secwatch.observer/filing/0001493152-26-030342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.